TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02247349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01799356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: daily 400 mg moksifloksasin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ofloxacin
Description: daily 800 mg oflaksasin plus 1000 mg metronidazol treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
Study: NCT04296812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Love Model
Description: The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness.
Study: NCT02138851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ficus Carica (300g/day)
Description: Ficus Carica (300g/day), parallel design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (300g/day)
Description: Placebo (300g/day), parallel design
Study: NCT04088812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental meat derivative + Placebo satiating control
Description: Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
Study: NCT01410097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes Support Education
Description: It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
Study: NCT02383017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shroom Tech Sport
Description: STS will be given every day in accordance to company guidelines for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
Study: NCT00683865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin
Description: Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg po od for 14 days
Study: NCT01446341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Below knee plaster casting
Description: Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional rehabilitation
Description: Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
Study: NCT00516659

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heat-Labile Enterotoxin of Escherichia coli (LT)
Description: Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
Study: NCT04358081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Hydroxychloroquine Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ+AZT
Description: Hydroxychloroquine with azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02530502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo focal RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04601766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
Description: Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2
Description: Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
Study: NCT03591874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
Study: NCT03390608

Intervention type: DRUG
Intervention: Endocrine therapy
Description: Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy versus no radiotherapy.

Intervention type: DRUG
Intervention: Herceptin
Description: Trastuzumab versus no trastuzumab (in women with HER2-positive disease).

Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy versus no chemotherapy.

Intervention type: PROCEDURE
Intervention: Type of breast cancer surgery
Description: Type of surgery (partial mastectomy, mastectomy, other).

Intervention type: OTHER
Intervention: Age at diagnosis
Description: Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).

Intervention type: OTHER
Intervention: Screen detected tumor
Description: Screening detected tumor (yes, no).

Intervention type: OTHER
Intervention: Menopausal status at diagnosis
Description: Menopausal status (premenopausal, postmenopausal).

Intervention type: OTHER
Intervention: Tumor size
Description: Tumor size (≤5 mm, 6-≤10 mm).

Intervention type: OTHER
Intervention: Estrogen receptor (ER) status
Description: ER-status (positive, negative).

Intervention type: OTHER
Intervention: Tumor grade
Description: Tumor grade (1, 2, 3).

Intervention type: OTHER
Intervention: HER2-status
Description: HER2-status (positive, negative).

Intervention type: OTHER
Intervention: Intrinsic subgroups of breast cancer
Description: Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
Study: NCT03624049

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Community based exercise programs held 2-3 times per week

Intervention type: OTHER
Group type: OTHER
Intervention: Health Class
Description: Community based health class held 1 time per week
Study: NCT01461096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV Vaccine
Description: Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine for Male Participants Only
Description: Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine for Female Participants Only
Description: Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
Study: NCT02679586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion weighted MRI
Study: NCT04316624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CAR066
Description: Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
Study: NCT03869125

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement
Description: Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
Study: NCT03700359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin
Description: Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Study: NCT00414050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Process Hepatitis B Vaccine (Experimental)
Description: Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
Study: NCT01842516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg
Description: LCB0-0371 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 1200mg
Description: LCB01-0371 1200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01652482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study: NCT01652482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
Study: NCT00414050

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine (Recombinant)
Description: RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine (Recombinant)
Description: ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
Study: NCT03390608

Intervention type: OTHER
Intervention: Nodal status
Description: N-status (N0, N1).
Study: NCT01961986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSR - traditional subscapularis release
Description: Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
Study: NCT02268097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing with freehand technique
Description: Preparing patellar resurfacing during total knee arthroplasty with freehand

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar resurfacing with resection guide technique
Description: Preparing patellar resurfacing during total knee arthroplasty with a resection guide
Study: NCT00720876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
Study: NCT02057107

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: 8.8-10 Gy per fraction (total: 44-50 Gy)

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: 8.8-10 Gy per fraction (total: 44-50 Gy)

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
Study: NCT00079274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: Locally Directed Therapy
Description: Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
Study: NCT02082717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: potassium chloride replacement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium chloride replacement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental - 4% Sodium Bicarbonate
Study: NCT01830140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Description: Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.03%
Description: Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
Study: NCT03919045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline injection
Description: Half of the patients will be randomized to saline injections into the neck and head muscles

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the group will be treated with needle stings without injections
Study: NCT01759056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVX 470
Description: active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03456401

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib or Sunitinib
Description: After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
Study: NCT03252756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytocannabinoid cannabidiol (CBD)
Description: CBD taken by mouth (PO)